IP Library Granted Patent US 6,992,110
Granted Patent B2
US 6,992,110 · App. 10/623,378 · Granted Jan 31, 2006

Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,992,110
App. No.
10/623,378
Granted
Jan 31, 2006
Kind
B2
Abstract

The present invention provides a method of treating fibromyalgia syndrome (FMS), chronic fatigue syndrome (CFS), and pain in an animal subject. The method generally involves administering a therapeutically effective amount of a dual serotonin norepinephrine reuptake inhibitor compound or a pharmaceutically acceptable salt thereof, wherein said dual serotonin norepinephrine reuptake inhibitor compound is characterized by a non-tricyclic structure and an equal or greater inhibition of norepinephrine reuptake than serotonin reuptake. In particular, the use of milnacipran to treat FMS, CFS, and pain is disclosed.

Claims (6)

1. A method of treating pain in an animal subject, comprising administering to an animal subject suffering from pain, an effective amount of milnacipran, or a pharmaceutically acceptable salt thereof, alone or in combination with a compound that is not phenylalanine, tyrosine or tryptophan.

2. The method according to claim 1 , wherein the compound is adjunctively administered with antidepressants, analgesics, muscle relaxants, anorectics, stimulants, antiepileptic drugs, sedatives, or hypnotics.

3. The method according to claim 1 , wherein the compound is adjunctively administered with neurontin, pregabalin, pramipexole, 1-DOPA, amphetamine, tizanidine, clonidine, tramadol, morphine, a tricyclic antidepressant, codeine, carbamazepine, sibutramine, valium, or trazodone.

4. The method according to claim 1 , wherein the animal subject is human.

5. The method according to claim 1 , wherein the amount administered is from about 25 mg to about 400 mg per day.

6. The method according to claim 1 , wherein the compound is formulated in a sustained release dosage formulation.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 21, 2017
From: ROYALTY PHARMA COLLECTION TRUST
To: FOREST LABORATORIES HOLDINGS LIMITED
Reel/Frame 041668/0583 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 28, 2013
From: CYPRESS BIOSCIENCE, INC.
To: SAVELLA AIV LLC
Reel/Frame 030890/0649 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 28, 2013
From: SAVELLA AIV LLC
To: ROYALTY PHARMA COLLECTION TRUST
Reel/Frame 030890/0657 →